Statements (50)
Predicate | Object |
---|---|
gptkbp:instance_of |
gptkb:drug
|
gptkbp:activities |
stimulates immune response
enhances T cell activation |
gptkbp:analyzes |
ongoing trials
post-transplant patients |
gptkbp:appointed_by |
intravenous infusion
|
gptkbp:benefits |
enhanced anti-tumor activity
|
gptkbp:can_be_used_with |
other immunotherapies
|
gptkbp:clinical_trial |
gptkb:United_States
Phase 1 NCT number pending publication |
gptkbp:collaborations |
academic institutions
|
gptkbp:developed_by |
Allo Vir
|
gptkbp:dosage_form |
determined by clinical trial
|
gptkbp:duration |
varies by protocol
|
gptkbp:feedback |
collected during trials
|
gptkbp:frequency |
once per treatment cycle
|
gptkbp:future_plans |
exploring combination therapies
|
https://www.w3.org/2000/01/rdf-schema#label |
Allo Stim
|
gptkbp:indication |
hematologic malignancies
|
gptkbp:invention |
patented
|
gptkbp:investment |
gptkb:healthcare_organization
|
gptkbp:is_a_source_of |
human cells
|
gptkbp:is_monitored_by |
required during treatment
|
gptkbp:is_used_for |
treatment of cancer
|
gptkbp:manager |
systemic administration
|
gptkbp:market |
not commercially available
|
gptkbp:origin |
derived from donor cells
|
gptkbp:project |
clinical development
|
gptkbp:publishes |
peer-reviewed journals
|
gptkbp:receives_funding_from |
private investment
|
gptkbp:regulatory_compliance |
not yet approved
investigational new drug |
gptkbp:research |
conducted in animal models
|
gptkbp:research_areas |
oncology
|
gptkbp:research_focus |
solid tumors
|
gptkbp:safety_features |
under evaluation
|
gptkbp:setting |
hospital or clinic
|
gptkbp:side_effect |
immune-related adverse events
monitored during trials |
gptkbp:sponsor |
Allo Vir, Inc.
|
gptkbp:student_enrollment |
specific inclusion criteria
|
gptkbp:target_audience |
cancer patients
|
gptkbp:targets |
gptkb:T_cells
|
gptkbp:treatment |
improve survival rates
measured in trials |
gptkbp:type |
gptkb:drug
|
gptkbp:bfsParent |
gptkb:Celularity_Inc.
|
gptkbp:bfsLayer |
6
|